Table 3 Zone of inhibition and minimum inhibitory concentration (MIC) of 2E,2′E) dibutylstannanediyl bis(4-((4-nitrophenyl)amino)-4-oxobut-2-enoate (DTN) against three strains of H.pylori, using disk diffusion method
From: Pharmacological evaluation of newly synthesized organotin IV complex for antiulcer potential
Samples | Zone of Inhibition (mm) | MIC (μg/mL) | ||||||
|---|---|---|---|---|---|---|---|---|
0.5 μg/disk | 1 μg/disk | 2 μg/disk | 4 μg/disk | 8 μg/disk | 16 μg/disk | 32 μg/disk | ||
STRAIN I: j63 (cagA-) | ||||||||
DTN | 2.33 ± 0.66 | 3.66 ± 0.33 | 4.66 ± 0.33 | 6.0 ± 0.57 | 10 ± 1.15 | 12.66 ± 0.33 | 15.33 ± 1 | 12 |
Metronidazole | 3.66 ± 0.33 | 4.66 ± 0.33 | 5.33 ± 0.66 | 7 ± 0.57 | 10.33 ± 1.20 | 14.66 ± 0.88 | 22 ± 1.15 | 4 |
STRAIN II: j196 (cagA-) | ||||||||
DTN | 3 ± 0.57 | 3.66 ± 0.66 | 5 ± 0.57 | 6 ± 1.73 | 9.33 ± 0.66 | 12.66 ± 0.88 | 19 ± 0.57 | 10 |
Metronidazole | 4 ± 0.57 | 5 ± 0.57 | 5 ± 0.57 | 7.33 ± 0.88 | 10.33 ± 1.20 | 15 ± 1.73 | 20.66 ± 2.30 | 6 |
STRAIN III: j107 (cagA+) | ||||||||
DTN | 2.66 ± 0.33 | 4 ± 0.57 | 4 ± 0.57 | 6.33 ± 0.66 | 10.33 ± 1.20 | 14 ± 0.57 | 18.66 ± 0.88 | 10 |
Metronidazole | 4 ± 0.57 | 4.66 ± 0.33 | 5.66 ± 0.88 | 8 ± 1.15 | 11.33 ± 0.66 | 15.66 ± 0.33 | 22.66 ± 0.66 | 4 |